10.73
price down icon2.45%   -0.27
 
loading
Schlusskurs vom Vortag:
$11.00
Offen:
$10.98
24-Stunden-Volumen:
1.92M
Relative Volume:
0.60
Marktkapitalisierung:
$837.57M
Einnahmen:
$65,400
Nettoeinkommen (Verlust:
$-46.34M
KGV:
-11.66
EPS:
-0.92
Netto-Cashflow:
$-38.74M
1W Leistung:
-5.38%
1M Leistung:
-16.11%
6M Leistung:
+56.87%
1J Leistung:
+10.28%
1-Tages-Spanne:
Value
$10.55
$11.06
1-Wochen-Bereich:
Value
$10.55
$11.71
52-Wochen-Spanne:
Value
$5.60
$17.43

CorMedix Inc Stock (CRMD) Company Profile

Name
Firmenname
CorMedix Inc
Name
Telefon
908-517-9500
Name
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Name
Mitarbeiter
14
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-25
Name
Neueste SEC-Einreichungen
Name
CRMD's Discussions on Twitter

Vergleichen Sie CRMD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CRMD
CorMedix Inc
10.73 858.65M 65,400 -46.34M -38.74M -0.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.79 106.37B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.46 59.90B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.63 60.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
796.92 49.56B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.10 36.88B 4.56B -176.77M 225.30M -1.7177

CorMedix Inc Stock (CRMD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-30 Herabstufung D. Boral Capital Buy → Hold
2025-06-30 Eingeleitet H.C. Wainwright Buy
2025-03-07 Eingeleitet Leerink Partners Outperform
2025-01-13 Eingeleitet D. Boral Capital Buy
2024-08-26 Eingeleitet Rodman & Renshaw Buy
2023-08-10 Eingeleitet RBC Capital Mkts Outperform
2021-02-17 Eingeleitet Needham Buy
2020-09-29 Eingeleitet JMP Securities Mkt Outperform
2020-09-21 Eingeleitet Truist Buy
2019-12-18 Eingeleitet B. Riley FBR Buy
2019-03-26 Bestätigt H.C. Wainwright Buy
2018-12-06 Eingeleitet ROTH Capital Buy
2017-09-25 Bestätigt H.C. Wainwright Buy
2017-08-10 Bestätigt Rodman & Renshaw Buy
2017-05-05 Bestätigt Rodman & Renshaw Buy
2016-11-11 Bestätigt FBR & Co. Outperform
2016-03-17 Bestätigt FBR Capital Outperform
2016-03-03 Eingeleitet FBR Capital Outperform
2015-11-16 Bestätigt ROTH Capital Neutral
2015-10-29 Bestätigt ROTH Capital Neutral
2015-05-06 Herabstufung ROTH Capital Buy → Neutral
2014-12-08 Bestätigt ROTH Capital Buy
2011-10-03 Herabstufung Maxim Group Buy → Hold
Alle ansehen

CorMedix Inc Aktie (CRMD) Neueste Nachrichten

pulisher
Oct 10, 2025

Is CorMedix Inc. stock reversal real or fakeWeekly Market Report & Capital Efficiency Focused Ideas - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Backtesting results for CorMedix Inc. trading strategiesJuly 2025 Drop Watch & Accurate Intraday Trading Signals - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

CorMedix: Challenging Long-Term Risk-Reward, Maintain Sell - Seeking Alpha

Oct 09, 2025
pulisher
Oct 09, 2025

Analyzing recovery setups for CorMedix Inc. investorsEntry Point & Fast Moving Market Watchlists - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Is CorMedix Inc. a candidate for recovery play2025 Historical Comparison & Consistent Growth Stock Picks - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Risk adjusted return profile for CorMedix Inc. analyzedJuly 2025 Spike Watch & Safe Entry Point Identification - newser.com

Oct 09, 2025
pulisher
Oct 07, 2025

Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In? - sharewise.com

Oct 07, 2025
pulisher
Oct 06, 2025

How cyclical is CorMedix Inc. (19KA) stock compared to rivalsJobs Report & Verified Swing Trading Watchlist - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Why CorMedix Inc. stock is in analyst buy zone2025 Institutional Moves & Consistent Profit Trade Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

CorMedix (CRMD): Assessing Valuation Following Phase III REZZAYO Trial Enrollment and Melinta Growth Moves - Sahm

Oct 05, 2025
pulisher
Oct 05, 2025

What analysts say about CorMedix Inc stockMoving Average Crossovers & Low Cost Market Strategies - earlytimes.in

Oct 05, 2025
pulisher
Oct 05, 2025

Is a relief rally coming for CorMedix Inc. holders2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Will CorMedix Inc. (19KA) stock benefit from Fed rate cutsJuly 2025 Final Week & Risk Managed Investment Signals - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves - The Globe and Mail

Oct 03, 2025
pulisher
Oct 03, 2025

CorMedix (CRMD): Assessing Valuation After Recent Volatility and Analyst Price Targets - Yahoo Finance

Oct 03, 2025
pulisher
Oct 03, 2025

What macro factors could drive CorMedix Inc. (19KA) stock higherJuly 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Is it too late to sell CorMedix Inc.Trade Signal Summary & Expert Verified Stock Movement Alerts - newser.com

Oct 02, 2025
pulisher
Oct 02, 2025

Real time scanner hits for CorMedix Inc. explainedCEO Change & Free Community Consensus Stock Picks - newser.com

Oct 02, 2025
pulisher
Oct 01, 2025

Is CorMedix Inc. building a consolidation baseDividend Hike & Smart Allocation Stock Reports - newser.com

Oct 01, 2025
pulisher
Sep 30, 2025

CorMedix files to sell 6.32M shares of common stock for holders - MSN

Sep 30, 2025
pulisher
Sep 30, 2025

CorMedix Bets Big On Melinta In $300 Million Deal - Finimize

Sep 30, 2025
pulisher
Sep 30, 2025

CorMedix completes enrollment in phase III fungal infection study By Investing.com - Investing.com Nigeria

Sep 30, 2025
pulisher
Sep 29, 2025

Cormedix announces completion of enrollment in phase III Respect clinical trial for Rezzayo - MarketScreener

Sep 29, 2025
pulisher
Sep 29, 2025

CorMedix completes enrollment in phase III fungal infection study - Investing.com

Sep 29, 2025
pulisher
Sep 29, 2025

Cormedix Announces Completion Of Enrollment In Phase Iii Respect Clinical Trial For Rezzayo - TradingView

Sep 29, 2025
pulisher
Sep 29, 2025

CorMedix Inc. Completes Enrollment in Phase III ReSPECT Study for REZZAYO® in Fungal Infection Prophylaxis, Topline Results Expected 2Q 2026 - Quiver Quantitative

Sep 29, 2025
pulisher
Sep 29, 2025

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO - Yahoo Finance

Sep 29, 2025
pulisher
Sep 29, 2025

Major Clinical Trial Progress: CorMedix's REZZAYO Could Transform Blood and Marrow Transplant Care - Stock Titan

Sep 29, 2025
pulisher
Sep 28, 2025

What drives CorMedix Inc stock priceSector ETF Performance & Unlock Smart Investment Tactics That Work - earlytimes.in

Sep 28, 2025

Finanzdaten der CorMedix Inc-Aktie (CRMD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.35
price down icon 5.74%
$83.80
price down icon 1.12%
$31.81
price down icon 0.13%
$102.06
price down icon 2.32%
$162.33
price down icon 1.26%
biotechnology ONC
$320.10
price down icon 4.68%
Kapitalisierung:     |  Volumen (24h):